AI for Healthcare Compliance Officers: Validate the Device, Surface the Reportable Event, Never Replace the MDR Coordinator

Healthcare compliance for AI-enabled medical devices is the highest-stakes profession in the AI compliance ecosystem. The FDA's January 2026 post-market shift moved weight from premarket review to post-market monitoring, Predetermined Change Control Plans, and Good Machine Learning Practice. The December 2024 PCCP final guidance reshaped how modifications get authorized. 21 CFR 803 Medical Device Reporting obligations remain unforgiving: missing a reportable adverse event has both regulatory and patient-safety consequences. And the volume of work — QSR documentation, PCCP scoping, adverse-event triage, 510(k) evidence mapping — has outrun the profession's growth, with 28% projected growth through 2030 and demand concentrated in digital-health companies.

This guide covers the four workflows where AI delivers the most leverage for working healthcare compliance officers in 2026: QSR + GMLP documentation gap audits, PCCP scope assessment, MedWatch reportability triage, and 510(k) Substantial Equivalence evidence mapping. The discipline that runs through all four: AI structures, surfaces factors, and prepares drafts; the MDR coordinator, the regulatory affairs lead, clinical leadership, and (where appropriate) external regulatory consultants make the determinations. No AI tool in this stack ever produces a reportability decision or a Substantial Equivalence argument — those remain qualified-personnel responsibilities.

QSR + GMLP Documentation Gap Audit

The FDA Quality System Regulation (21 CFR 820, transitioning to the QMSR aligned to ISO 13485) defines the documentation expected from a medical device manufacturer. For AI/ML-enabled medical devices, the QSR intersects with IEC 62304 software lifecycle documentation, ISO 14971 risk management, IEC 62366 usability, FDA premarket cybersecurity expectations, and the 10 Good Machine Learning Practice guiding principles. Auditing whether the documentation package is complete enough for a submission — and which gaps are submission-blockers vs best-practice improvements — is week-long work done well, half-day work done badly.

The QSR + GMLP Documentation Gap Audit tool takes the device description, intended use, classification/path, current documentation state, and known open issues. It produces a QSR Subpart map (per applicable Subpart: documentation expected, current state, likely-gap flag), GMLP alignment notes against the 10 guiding principles, and a P0/P1/P2 ranked gap report with citations and owners.

What separates a useful gap audit from a useless one

• Subpart-specific, not generic. "Improve documentation" is not a finding. "21 CFR 820.30(c) Design Input documentation is incomplete — user needs and intended use are documented, but the design inputs derived from those user needs are not traceable in the current Design History File" is
• GMLP principle-by-principle, not aggregate. The 10 GMLP principles each have specific evidence expectations. "Aligned with GMLP" without naming which principles, what evidence, and what's still missing produces audits that look thorough and aren't
• Subgroup performance flagged separately. FDA has been increasingly attentive to subgroup performance in AI/ML SaMD reviews. Validation evidence that doesn't address demographic strata and clinically-relevant strata is a P0 gap for any device with diverse intended-use populations
• Cybersecurity is underaddressed in most AI/ML SaMD packages. The FDA premarket cybersecurity guidance (and post-market cybersecurity expectations) is a frequent point of FDA review comment. SBOM, threat modeling, and security risk management need explicit documentation
• PCCP readiness checked as a separate dimension. Whether the device's expected modification space can be handled via a Predetermined Change Control Plan is a strategic question that affects the documentation requirements. Surface it during the gap audit, not later

The audit is preparatory analysis. The responsible quality function — not the audit tool — remains responsible for compliance with 21 CFR 820 / QMSR, GMLP, and applicable post-market expectations.

PCCP Scope Audit

The December 2024 FDA final guidance on "Predetermined Change Control Plans for Machine Learning-Enabled Device Software Functions" formalized the framework that lets manufacturers authorize anticipated modifications without re-submitting. The three required PCCP sections — Description of Modifications, Modification Protocol, Impact Assessment — define the envelope of changes a manufacturer can make to a cleared device without a new 510(k) / De Novo / PMA. Deciding whether a proposed change fits the envelope, requires a PCCP amendment, or triggers a new submission is week-long work involving regulatory affairs, clinical leadership, and frequently external counsel.

The PCCP Scope Audit tool takes the device context, the proposed change, an existing PCCP summary, and the modification driver. It produces a per-section scope assessment against each of the three PCCP sections, a three-section analysis (if amendment is needed), and a recommendation with specific questions for regulatory affairs, clinical lead, and external counsel.

The PCCP scope discipline

• Section-by-section assessment, not gestalt. The proposed change either fits the Description of Modifications (the anticipated modification space) or it doesn't. The Modification Protocol either covers the verification approach for this change or it doesn't. The Impact Assessment either contemplates the new risk profile or it doesn't. Each section is its own test
• Partial fit usually means amendment, not new submission. A modification within the spirit but not the letter of the PCCP can often be handled via a PCCP amendment / engineering change order rather than a full new 510(k) — but the team needs to be honest about which sections require updating
• Intended-use changes are almost never within PCCP scope. The PCCP authorizes modifications to a device with stable intended use. Expanding intended use, expanding patient population beyond the impact assessment, or introducing a new failure mode the impact assessment doesn't contemplate typically requires a new submission. Don't try to fit intended-use expansion into a PCCP
• Post-market-driven modifications have parallel obligations. A change driven by an adverse-event cluster or performance signal may trigger 21 CFR 803 reporting and 21 CFR 820.100 CAPA obligations regardless of whether the mechanical change fits the PCCP. Surface this connection
• Cybersecurity and labeling implications are separate dimensions. A model change that mechanically fits the PCCP can still have cybersecurity implications (new dependencies, expanded attack surface) or labeling implications (performance characteristics changed, new claims) that warrant separate analysis

The tool produces a recommendation; the regulatory affairs lead — in consultation with clinical leadership and (where the change is non-trivial) external regulatory counsel — produces the submission-pathway determination.

MedWatch Reportability Triage

This is the highest-stakes single workflow in the healthcare compliance officer's portfolio. 21 CFR 803 Medical Device Reporting obligations require manufacturers to report events where a device "may have caused or contributed to a death or serious injury" (§803.50(a)(1)) or where a device malfunctioned in a way that, if recurred, would be likely to cause or contribute to death or serious injury (§803.50(a)(2)). The reporting timeline is 30 days for death/serious injury, 5 days for events requiring remedial action to prevent unreasonable risk of substantial harm. Missing a reportable event has severe regulatory consequences and — more importantly — worse patient-safety consequences.

The MedWatch Reportability Triage tool takes the device description, the event details (PHI stripped), the patient outcome, the causality hypothesis, and the reporter context. It produces §803.50 reportability factor analysis, a starting framework for the 3500A form (with PHI placeholders for the MDR coordinator to fill from de-identified source records), and escalation questions including cluster-pattern check and CAPA implications.

Why this tool's framing is the strictest in the entire AI Career Lab toolkit

• The MDR coordinator — not this tool, not the compliance officer alone — makes the reportability determination. The tool surfaces factors pointing toward reportability and factors pointing away. It does not produce a "reportable" or "not reportable" conclusion. The determination is the MDR coordinator's
• The tool errs toward escalation, never away from it. Over-reporting carries minimal regulatory consequence and demonstrates good faith. Under-reporting carries severe regulatory and worse patient-safety consequence. When the inputs leave room for interpretation, the tool's output points toward escalation
• Strip PHI before pasting. The tool generalizes patterns; it does not need names, MRNs, dates of birth, or identifying details. PHI in the input creates Privacy Rule exposure
• Reportability uncertainty is itself a finding. If the causality is unclear, if the patient outcome is unknown, if the reporter context suggests user-facility or importer parallel obligations — these uncertainties feed directly into the escalation questions. Uncertain inputs produce escalation outputs, not best-guess conclusions
• Cluster pattern check is separate. A single event may be one-off; the same event type from multiple users in a short window is a quality system signal triggering different obligations under §803.17 and §820.100 CAPA. The triage flags whether the event suggests a cluster

The disclaimer for this tool is the strongest on the site: when in doubt about reportability, the doubt itself is the answer. Escalate to the MDR coordinator and consult FDA guidance directly.

510(k) Substantial Equivalence Evidence Mapping

For a 510(k) submission, the Substantial Equivalence argument is the spine of the entire submission. It rests on two questions: (1) does the new device have the same intended use as the predicate? (2) does it have the same technological characteristics, or different characteristics that do not raise different questions of safety and effectiveness and that the performance data demonstrate substantial equivalence for? Building the SE argument is regulatory affairs work in consultation with clinical leadership; structuring the evidence the SE argument is built from is where the compliance officer adds leverage.

The 510(k) Substantial Equivalence Evidence Mapping tool takes the device description, predicate context, clinical evidence available, performance testing available, and known differences from the predicate. It produces a Substantial Equivalence map (intended-use comparison + side-by-side technological characteristics + performance data comparison), evidence gaps and questions (per gap: current evidence, FDA expectation, recommended next step, owner), and pre-submission preparation topics (specific Q-Sub topics where FDA input would meaningfully change submission strategy).

What the SE evidence mapping does and doesn't do

• Does: Structure the evidence package against the FDA Substantial Equivalence framework. Surface where the evidence supports the SE argument and where it falls short of FDA expectations
• Does: Flag the intended-use comparison as the threshold test. If intended use materially differs from the predicate, 510(k) may not be the right pathway — consider De Novo or PMA
• Does: Address the "different questions of safety and effectiveness" analysis for technological characteristic differences. This is where many 510(k) submissions get hung up at FDA review
• Does: Surface Q-Sub (pre-submission) topics for FDA input. The Q-Sub is the highest-leverage way to de-risk a 510(k) and is underused. Topics where FDA input would meaningfully change submission strategy go on the Q-Sub agenda
• Doesn't: Produce the Substantial Equivalence argument itself. That's regulatory affairs work in collaboration with clinical leadership
• Doesn't: Determine the submission pathway. If the evidence mapping suggests SE may be a stretch, that's a question for regulatory affairs and external consultants, not a conclusion the tool produces

Where AI Stops and You Start

AI structures the evidence, surfaces gaps, prepares triage analyses, and drafts submission scaffolding. You handle everything that constitutes the actual compliance and patient-safety function:

• Reportability determinations. The MDR coordinator makes the call. The compliance officer escalates. AI prepares the triage. Never the other way around
• Submission-pathway determinations. Regulatory affairs decides whether a change fits a PCCP, requires amendment, or triggers a new submission. AI structures the analysis; regulatory affairs decides
• Substantial Equivalence arguments. Regulatory affairs and clinical leadership build the SE argument. AI maps the evidence; the argument is theirs
• Clinical safety decisions. Whether to limit an indication for use based on subgroup performance, whether to issue a field safety notice, whether to recall a device. AI surfaces the data; clinical and regulatory leadership decide
• Patient-safety escalation. When something doesn't feel right — when a complaint pattern is emerging, when a subgroup is performing differently, when an operator reports an unexpected behavior — the escalation belongs to qualified clinical and regulatory personnel. AI is the triage layer, not the safety net

The healthcare compliance officer is the single point of accountability for medical-device quality and post-market safety. AI is the tool that lets that accountability scale across more devices, more events, and more submissions. AI is not — and should not become — the single point of failure for patient safety.

Getting Started

If you're building the healthcare compliance AI workflow for the first time:

1. Pick one device in your portfolio. Run the QSR + GMLP Documentation Gap Audit tool. Compare its findings to your last manual gap audit; note what it caught and what it missed
2. For your next proposed device modification, run the PCCP Scope Audit tool. Bring the output (especially the questions for regulatory affairs) to your next review meeting
3. For your next adverse event triage, run the MedWatch Reportability Triage tool. Use the output to escalate to the MDR coordinator with structured factor analysis
4. For your next 510(k) prep, run the 510(k) Substantial Equivalence Evidence Mapping tool. Use it to drive the Q-Sub agenda

Explore all of our free healthcare compliance officer AI tools for the full workflow set, or read the Claude Cowork playbook for healthcare compliance officers for the prompt structures behind these tools.

---

*This article is general guidance for healthcare compliance officers. FDA regulations (21 CFR 820 / QMSR, 21 CFR 803, the December 2024 PCCP final guidance, premarket and post-market cybersecurity guidance, GMLP guiding principles), international standards (ISO 13485, IEC 62304, ISO 14971, IEC 62366), and sector-specific obligations are evolving and jurisdiction-specific. The tools described produce preparatory analysis and starting structures — they do not produce regulatory determinations, reportability decisions, Substantial Equivalence arguments, or compliance opinions. Qualified regulatory affairs personnel, clinical leadership, the MDR coordinator, and (where appropriate) external regulatory counsel remain authoritative for those determinations. When in doubt about reportability, escalate.